TRCT
EPRS

Tower Research Capital (TRC)’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Tower Research Capital (TRC)’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,288
Closed -$3K – 5611
2016
Q1 		$3K Sell
1,288
-1,947
-60% -$5.47K ﹤0.01% 3297
2015
Q4 		$10K Sell
3,235
-886
-21% -$3.99K ﹤0.01% 2225
2015
Q3 		$18K Buy
+4,121
New +$24.2K ﹤0.01% 1859
2015
Q2 		– Sell
-333
Closed -$3K – 5771
2015
Q1 		$3K Buy
333
+186
+127% +$1.49K ﹤0.01% 3700
2014
Q4 		$1K Sell
147
-63
-30% -$329 ﹤0.01% 3916
2014
Q3 		$2K Buy
+210
New +$1.81K ﹤0.01% 4027

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return